title: Time to stop progesterone receptor testing in breast cancer management.
authors.forename: Ivo A
authors.initials: IA
authors.lastname: Olivotto
authors.forename: Pauline T
authors.initials: PT
authors.lastname: Truong
authors.forename: Caroline H
authors.initials: CH
authors.lastname: Speers
authors.forename: Vanessa
authors.initials: V
authors.lastname: Bernstein
authors.forename: Sharon J
authors.initials: SJ
authors.lastname: Allan
authors.forename: Seamus J
authors.initials: SJ
authors.lastname: Kelly
authors.forename: Mary L
authors.initials: ML
authors.lastname: Lesperance
mesh_terms: D001943:Breast Neoplasms / Q000473:pathology* / Q000628:therapy*; D003362:Cost-Benefit Analysis; D003657:Decision Making; D005260:Female; D006801:Humans; D007150:Immunohistochemistry; D008875:Middle Aged; D009362:Neoplasm Metastasis; D009367:Neoplasm Staging / Q000191:economics / Q000379:methods*; D010347:Patient Care Planning; D011237:Predictive Value of Tests; D011379:Prognosis; D011980:Receptors, Progesterone / Q000032:analysis*
chemical_list: D011980:Receptors, Progesterone